Answers are grounded in this paper and cite their sources.
In non-small-cell lung cancers (NSCLC) with programmed death-ligand 1 (PD-L1) expression on ? 50% of tumor cells, first-line treatment with the PD-1 inhibitor pembrolizumab improves survival compared with platinum-doublet chemotherapy.
No takes yet. Share an insight, caveat, or question.
Cabezón‐Gutiérrez et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: